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Abstract: The placenta is the primary interface between the fetus and mother and plays an
important role in maintaining fetal development and growth by facilitating the transfer of
substrates and participating in modulating the maternal immune response to prevent
immunological rejection of the conceptus. The major substrates required for fetal growth
include oxygen, glucose, amino acids and fatty acids, and their transport processes depend
on morphological characteristics of the placenta, such as placental size, morphology, blood
flow and vascularity. Other factors including insulin-like growth factors, apoptosis,
autophagy and glucocorticoid exposure also affect placental growth and substrate transport
capacity. Intrauterine growth restriction (IUGR) is often a consequence of insufficiency, and
is associated with a high incidence of perinatal morbidity and mortality, as well as increased
risk of cardiovascular and metabolic diseases in later life. Several different experimental
methods have been used to induce placental insufficiency and IUGR in animal models and
a range of factors that regulate placental growth and substrate transport capacity have been
demonstrated. While no model system completely recapitulates human IUGR, these animal
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models allow us to carefully dissect cellular and molecular mechanisms to improve our
understanding and facilitate development of therapeutic interventions.
Keywords: placental morphology; vascularity; substrate transport; IUGR

1. Introduction
In eutherian mammals, the placenta is the primary interface between the fetus and mother. One of the
main functions of the placenta is to deliver nutrients and oxygen to the fetus. Failure of the placenta to
deliver an adequate supply of nutrients to the fetus is termed placental insufficiency and results in
intrauterine growth restriction (IUGR), affecting up to 5%–10% of pregnancies in developed
countries [1–3]. IUGR is also associated with a high incidence of perinatal morbidity and mortality and
an increased risk of cardiovascular disease and type II diabetes in later life [4–7]. In this review, we will
focus on placental structure and function, factors affecting placental nutrient transport capacity, animal
models of IUGR and regulation of placental growth and substrate transport in the IUGR pregnancy.
2. Placental Structure and Function
In mammals, the placenta is the primary interface between the fetus and mother and plays an
important role in maintaining fetal growth by performing several physiological functions, which,
following birth, are controlled by the kidney, gastrointestinal tract, lungs and endocrine glands. The main
functions of the placenta include modulation of the mother’s immune response to prevent immunological
rejection termed tolerance, facilitating the exchange of respiratory gases, water, ions, nutrients and
wastes between the maternal and fetal circulations, and producing and secreting hormones, cytokines
and other signalling molecules required to maintain pregnancy and to ensure placental and fetal
development and growth [8].
Maternal blood supply to the placenta is established at the end of the first trimester of human
pregnancy, with maternal blood entering the intervillous space of the placenta from the transformed
spiral arterioles for substrate transport to the fetus [9–11]. The barrier between the maternal and the fetal
circulations in the human hemochorial placenta consists of three fetal cellular layers: (i) the
syncytiotrophoblast, a multinucleated epithelial layer formed following the fusion of the mononucleated
villous cytotrophoblasts; (ii) villous stromal tissue and (iii) the fetal capillary endothelium (Table 1) [12].
The syncytiotrophoblast has two polarized plasma membranes: the maternal-facing microvillous plasma
membrane (MVM) and the basal membrane (BM). The syncytiotrophoblast is the main regulator of
substrate exchange and nutrient transporters are expressed on both plasma membranes [13].

Nutrients 2015, 7

362

Table 1. An across species comparison of placental shape and structure [14–16].
Species
Humans
Ruminants (Sheep, cattle, goats)
Rodents (rats, mice)
Pigs
Horses
Carnivores (cats, dogs)
Primates

Placental Shape
Discoid
Cotyledonary
Discoid
Diffuse
Diffuse
Zonary
Discoid

Placental Structure
Hemochorial
Epitheliochorial
Hemochorial
Epitheliochorial
Epitheliochorial
Epitheliochorial
Hemochorial

It is important to understand the role of placental function in the IUGR fetus from a clinical and
scientific point of view. However, in vivo studies of the human placenta are difficult as the methodology
presents risks to both the mother and fetus. Therefore, the majority of the body of knowledge about the
placenta and its function is a result of ultrasound studies across gestation or those performed in placentas
collected at delivery or in animal models. In terms of morphological similarities, the placenta of higher
primates is the most comparable to that of the human, with a discoid hemomonochorial structure, where
fetal trophoblast cells are in direct contact with the maternal blood supply [15]. However, primates that
are suitable for experimental studies are small, have small fetuses, and often abort or deliver prematurely
following intrauterine surgery, limiting their use in placental studies [17]. Therefore placental nutrient
transport and exchange has been extensively studied in the rabbit, guinea pig, rat, mice and human [18–20].
However, one of the most widely used animal models for studies of fetal development and placental
function is the sheep [21–23].
One of the advantages of working with sheep compared to other animal models of pregnancy is that
the functional responses of the sheep fetus to short or long periods of placental insufficiency can be
studied in utero [24–28]. Like the human, organogenesis in the sheep occurs during early gestation with
the functional maturation of the renal and cardiovascular systems by late gestation [23]. In addition,
pregnant ewes are comparable to humans in size with equally large fetuses that tolerate intrauterine
surgery well and most organ systems develop before birth [29]. Therefore, vascular catheters can be
surgically implanted in the fetus, exteriorized through the ewes’ flank and maintained for several weeks,
allowing for repetitive blood sampling from unanaesthetised pregnant ewes and their fetuses to measure
blood gases, hormones and cardiovascular parameters in response to placental insufficiency during late
gestation [23,30].
In sheep, implantation begins at ~14–16 days gestation (term = 150 ± 3 days gestation) and is complete
by ~22 days gestation, marking the initiation of placentation [31], which is the process of placental
growth and development, resulting in the maturation of functional units called placentomes. Sheep have
a non-invasive, cotyledonary type of placentation in which specialized areas of the endometrium termed
caruncles are attachment sites for trophoblasts of the chorion forming 50–90 placentomes during a
normal singleton pregnancy (Table 1) [14,16]. Placentomes are divided into the maternal (caruncle) and
fetal (cotyledon) portions and consist of interdigitated maternal crypts and fetal villi that develop through
synchronised growth between the trophoblast and caruncular endometrium [16,32]. Morphologically,
the maternal portion of the placentome is composed of maternal connective tissue, maternal capillaries
and maternal epithelial cells; while the fetal portion of the placentome is composed of fetal trophoblasts,
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connective tissue and fetal capillaries. The placentomes grow rapidly following implantation and reach
maximum weight at ~75–80 days gestation, from which point weight declines until term [33]. However,
placentomes undergo progressive structural remodelling, with attenuation of all cell layers in both fetal
and maternal tissues, bringing fetal and maternal capillaries in close proximity to allow increased capacity
for substrate transfer during the second half of gestation when fetal demand for nutrients is high [16].
Placentomes are classified into four types (A–D) based on their gross morphology [34]. The fetal side
of the placentome is defined as a thin hemophagous zone where maternal blood extravasates between
the maternal crypts and fetal villi. Type A placentomes are rounder in shape and the hemophagous zone
is inverted inside of the bulk of the placentome in which only a small area of the zone is visible externally.
Type D placentomes are flatter in shape and the hemophagous zone is everted and covers the entire fetal
surface of the placentome. Type B and C placentomes are intermediate in the degree of hemophagous
zone eversion that is present. Throughout gestation, type A and B placentomes dominate, accounting for
~60% of the total number in a normal pregnancy. Type C and D placentomes are less common, occurring
with greater frequency in multiple pregnancies and during late gestation. They are larger, heavier and
more everted compared to type A placentomes. Although, the placentome types have different structures,
it is not known if they have differential functions [32]. Previous studies have suggested that placentome
eversion is an adaptation that occurs to increase the efficiency of placental nutrient transfer to the
fetus [35]. In sheep, gross placentome morphology changes progressively throughout gestation with an
increase in the number of everted placentomes, type C and D, in late gestation at 125–135 days [35,36].
Interestingly, it has been reported that early exposure to high plasma cortisol concentrations decreases
the proportion of type C and D placentomes, which indicates that developmental shifts in placentome
classification are not restricted to eversion [16].
3. Factors Affecting Placental Substrate Transport Capacity
Birth weight depends not only on maternal nutrition but also on the placenta’s ability to transport
substrates from the maternal to the fetal circulation [10]. Placental efficiency or fetal-placental weight
ratio, defined as grams of fetus per gram of placenta, can vary between species and pregnancies [37]. At
any gestational age, placental efficiency measurements provide an indication of the conditions
experienced in utero and the extent to which placental adaptations during intrauterine development have
occurred in order to meet fetal growth demands. These morphological and/or functional adaptations
determine placental substrate transport capacity and efficiency to the fetus. The major substrates required
for fetal growth include oxygen, glucose, amino acids and fatty acids [9,12,13].
While the placenta regulates the transport of nutrients to the fetus according to the mother’s ability to
deliver them, fetal demands as well as hormones and growth factors secreted by the placenta, the weight,
size and shape of the placenta also affect its ability to transfer nutrients [38–40]. The transfer of highly
permeable molecules, such as gases, oxygen and carbon dioxide, is influenced by blood flow and occurs
via simple diffusion, whereas less permeable substrates are transferred through passive and active
transport processes. Glucose is transported across the placenta via facilitated diffusion and is
orchestrated by hormones secreted by the placenta [11]. Therefore, net glucose transfer is highly
dependent on the maternal-fetal concentration gradient. Nutrients such as amino acids are transported
via active transport using the charge provided by sodium ions and those that are transported via exchange
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for another amino acid [13]. Furthermore, these processes also depend on morphological characteristics
of the placenta, such as placental size, surface area for exchange, vascularity as well as blood flow [15].
3.1. Fetal Oxygenation
Simple molecules such as oxygen and carbon dioxide are transported by diffusion and bulk flow.
Oxygen (O2) plays a critical role in the development and function of the placenta and fetal hypoxaemia
is a common condition of complicated pregnancy. Oxygen diffuses from the maternal to the fetal
circulation across a placental epithelial layer that consumes O2. This O2 consumption generates a
transepithelial oxygen partial pressure (PO2) difference whose magnitude depends upon the rate of
umbilical and uterine blood flow, fetal and maternal blood oxygen carrying capacity, haemoglobin
oxygen binding affinity, placental surface area and placental permeability [41]. Placental gas exchange
occurs across cellular layers between the uterine and fetal circulations, once vascular beds have matured
to allow adequate supply across the two circulations [14]. As a result, placental oxygen levels are low in
the first trimester, increasing significantly by the second trimester. Therefore the fetus develops in a
hypoxic environment during early pregnancy until the utero-placental vasculature can provide efficient
gas exchange. Currently, much of the understanding of fetal and placental respiration is from the study
of sheep in late gestation [42]. As the placenta is a highly metabolically active organ, it consumes a large
quantity of the oxygen taken up from maternal circulation; some 80% in mid-gestation [42] and
40%–60% in late gestation [43]. Moreover, despite decreases in maternal oxygenation and uterine blood
flow, the PO2 gradient across the placenta remains constant in order to sustain fetal oxygen delivery at a
normal rate [44].
3.2. Placental Size and Morphology
Placental size has a direct effect on the capacity for nutrient transfer via changes in surface area for
transport. Placental weight is positively correlated with birth weight at term in many animal models [15].
In humans, placental weight progressively increases throughout pregnancy, while in rodents and sheep,
placental weight increases before plateauing in mid to late gestation and then declines until term [45].
The small placenta increases nutrient transport capacity via morphological adaptations such as increased
relative surface area for nutrient exchange, vascularity and decreased barrier thickness. These
adaptations affect placental transport capacity and alter fetal to placental weight ratio.
3.3. Blood Flow and Vascularity
Blood flow is a major determinant of placental function and fetal growth. Vascularity of the sheep
placenta increases in mid gestation, due to increases in the number and surface density of the placental
capillaries, particularly those in the fetal side of the placentomes [46]. Vasculogenesis, formation of new
blood vessels, and angiogenesis, formation of new branches from pre-existing vessels [47], are critical
to form a vascular system needed for effective transport of nutrients, oxygen, and waste products. Several
factors have been identified as important regulators of these processes, including the vascular endothelial
growth factor (VEGF) family, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF),
platelet-derived growth factor (PDGF) and angiopoietin-1 and -2 [48]. The VEGF proteins and receptors
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VEGFR1 (FLT-1) and VEGFR2 (FLK-1) are the most studied family of growth factors known to
regulate the processes of vasculogenesis and angiogenesis. In pregnancy, VEGF is expressed by human
villous and extravillous trophoblasts and also participates in the proliferation, migration, and metabolic
activity of trophoblasts [49]; bFGF acts as a modulator of tissue differentiation and placental
angiogenesis [48]. Angiopoietin-1 and its antagonist angiopoietin-2 act on the angiopoietin receptor
(TIE-2) to regulate vascular integrity and remodeling [50]. Angiopoietin-1 and -2 have both been
detected in decidual and placental tissues [51]. Vascular growth is necessary to increase placental-fetal
blood flow across gestation [52–54]. Therefore fetal growth is linked to the capacity of the placenta to
supply oxygen and nutrients for transfer to the fetus [55].
3.4. Insulin-Like Growth Factors
Insulin-like growth factors (IGFs), IGF-1 and IGF-2, are single chained polypeptides that promote
fetal and neonatal growth, acting in response to fetal, maternal and placental signals such as nutrients,
oxygen and hormones via the IGF receptors, IGF-1R and IGF-2R, and the insulin receptor (InsR).
IGF-2 is the most abundant of the fetal IGFs, however, deletion of either Igf gene results in reduced birth
weight [55]. IGF-1 regulates fetal growth in response to nutrient availability while IGF-2 stimulates
placental growth and differentiation [56]. Furthermore IGFs regulate substrate transport and hormone
secretion and influence fetal growth indirectly by influencing maternal substrate availability or directly
by influencing placental nutrient uptake and transport [56]. In human trophoblasts, IGF-1 and IGF-2
stimulate glucose and amino acid uptake [57]. Elevated maternal plasma IGF-1 has been shown to
increase fetal glucose and amino acid uptake in the guinea pig in early pregnancy [27,28]. In sheep,
elevated plasma IGF-1 concentrations in early pregnancy are associated with increased maternal plasma
glucose concentrations and enhanced fetal growth [56]. Furthermore in late pregnancy, acute treatment
with IGF-1 alters placental metabolic function and increases glucose delivery to the sheep fetus [58].
IGF-1 stimulates system A amino acid uptake in cultured trophoblast cells and can act by both the
IGF-1R and InsR [57]. Interestingly, in a knockout mouse model, deletion of the gene transcript for
placenta specific expression of Igf2 results in the reduction of placental growth while fetal growth is
maintained in association with an up-regulation of glucose transporter (GLUT3) and amino acid
transporter (SNAT2) during mid gestation, however IUGR still develops near term [59–61].
3.5. Placental Apoptosis, Autophagy and Glucocorticoid Actions
The role of the apoptosis cascade has been characterized in human villous trophoblast turnover and
syncytium formation [62]. Apoptosis occurs in placentas of normal human pregnancies, and is regulated
by the effector caspase pathway and the apoptosis inhibitor B-cell lymphoma 2 (BCL-2) in the
trophoblast [62].
Autophagy is a highly regulated and dynamic process involving invagination and degradation of
cytoplasmic components that maintain cellular homeostasis and promote cell survival in response to
environmental stresses such as starvation and hypoxia [63]. Autophagy-related proteins such as beclin-1,
light chain 3 isoform B (LC3B), and damage-regulated autophagy modulator (DRAM) are present in the
trophoblast of human placenta during early, mid and late gestation [64,65]. Beclin-1 is part of an early
complex that promotes synthesis and growth of pre-autophagosomal membranes [66]. LC3B is
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synthesized as proLC3B and converted to LC3B-I by autophagy-related proteases, which is further processed
into LC3B-II and integrated into membranes of autophagosomes upon induction of autophagy [66]. DRAM
is a lysosomal protein that regulates autophagy in a p53-dependent manner [67].
In utero, the placenta and embryo/fetus are each exposed to physiological glucocorticoids arising
from either the maternal or fetal adrenal glands. Glucocorticoid actions are moderated by the
glucocorticoid receptor and two isoforms of intracellular 11β-hydroxysteroid dehydrogenases
(11βHSDs) [68]. 11βHSD1, which is a reduced nicotinamide adenine dinucleotide phosphate-dependent
isoform, acts to convert biologically inert cortisone to the active cortisol, whereas 11βHSD2, which is a
unidirectional nicotinamide adenine dinucleotide-dependent enzyme, catalyzes the conversion of the
biologically active cortisol to the inert cortisone. In placenta, 11βHSD1 protein is expressed specifically
in the placental villous endothelial cells, amnion, chorionic and extravillous trophoblasts, while
11βHSD2 protein is localized exclusively in the syncytiotrophoblast and invasive extravillous
trophoblasts with no expression in the chorion or amnion [69]. 11βHSD1 expression increases
throughout pregnancy in response to progesterone in human placenta [70]. In human pregnancy,
placental 11βHSD2 activity increases markedly in the third trimester of pregnancy at a time when
maternal circulating levels of glucocorticoid are rising [71]. In contrast, the placental inactivation of
cortisol via placental 11βHSD2 activity decreases in the latter stages of gestation in sheep and is not
present in term ovine placenta [72]. The fetus is normally protected from the high levels of maternal
cortisol by placental 11βHSD2 [69].
3.6. Placental Transporter Abundance
The placenta’s ability to transport substrates for fetal growth is also influenced by the abundance,
activity and localization of transporters in the placental membranes [73]. Furthermore, transport of
nutrients such as glucose and amino acids is also determined by the placental barrier and specifically the
expression and activity of particular nutrient transport systems in the placental syncytiotrophoblast
plasma membranes, MVM and BM [9]. Glucose and amino acid uptake into fetal circulation is dependent
on three steps: (1) uptake from maternal circulation by transporters on the microvillous membrane of the
syncytiotrophoblast; (2) transport across cytoplasm of the syncytiotrophoblast; and (3) transport across
the fetal-facing basal membrane of the syncytiotrophoblast into fetal circulation [14]. Enhanced
expression of nutrient transporters per unit of surface area is another key compensatory mechanism used
to increase efficiency of the small placenta. Activity of placental glucose and amino acid transport
systems is influenced by a wide range of environmental factors including heat stress, hypoxia,
under- and overnutrition as well as exposure to placental hormones [55]. Placental glucose, amino acid
and fatty acid transport systems are discussed in detail below.
3.6.1. Placental Glucose Transport Systems
Glucose is the primary nutrient required for the fetus and placenta [13,74]. However, the fetus and
placenta have a limited ability for producing glucose, therefore glucose availability is dependent on
supply from the maternal circulation [13,75–77]. Placental glucose uptake and transport to the fetus
occurs down the concentration gradient from maternal to fetal circulation where it crosses the placental
barrier via facilitated transport [14,78]. This is mediated by a family of sodium-independent transporter
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proteins, encoded by 14 different genes of the SCL2A family, called glucose transporters (GLUTs) [78].
GLUTs are present on both plasma membranes of the syncytiotrophoblast [13]. As glucose is transported
down the concentration gradient, higher maternal glucose concentrations compared to fetal glucose
concentrations drive net glucose transport toward the fetus. A high density of GLUTs in the MVM,
together with a large surface area, allows for rapid glucose uptake into the syncytiotrophoblast. This
provides adequate glucose supply for placental consumption while also maintaining a gradient between
the syncytiotrophoblast and fetal circulation, ensuring fetal supply [13]. GLUT expression on the BM is
much lower than the MVM and is associated with a smaller placental surface area, which suggests
transport across the BM is the rate-limiting step of placental glucose metabolism [9,13]. The sheep and
human placenta have two primary glucose transporters including GLUT1 (SLC2A1) and GLUT3
(SLC2A3) and less abundant glucose transporters including GLUT4 (SLC2A4) and GLUT8 (SLC2A8).
GLUT1 is insulin independent and ubiquitously expressed in a variety of human tissues including
muscle, adipose, brain and endothelial cells [74]. GLUT1 is the main glucose transporter in the placenta
and is highly expressed on both the microvillous and basal membranes of the syncytiotrophoblast [13,79].
In humans, GLUT1 expression is higher in the MVM compared to the BM, allowing for increased
glucose uptake from maternal circulation [9,80]. In sheep, GLUT1 is localised to the base of the syncytial
layer of the placenta, which is derived from the maternal epithelial cells and chorionic binucleated cells,
and the baso-lateral surface of the trophoblast layer [81]. However, GLUT1 has not been found on the
interdigitated microvilli of the trophoblast and syncytial layer [14]. In sheep, placental GLUT1 mRNA
expression increases throughout gestation, peaking at 120 days in singleton pregnancies and 140 days in
twins [79].
GLUT3 is insulin independent and its expression is cell-specific, depending on the stage of
pregnancy [78]. In both humans and sheep, GLUT3 is expressed throughout gestation but decreases
toward term, and therefore plays a greater role in the transport of glucose during early fetal
development [74,78]. Furthermore, GLUT3 expression in the placenta has been detected in the
cytotrophoblast but not the syncytiotrophoblast in the first trimester of human pregnancy [78]. However,
in the third trimester placental GLUT3 expression is localised to the vascular endothelial cells of the
fetal blood vessels and stromal cells [14,78,80]. In sheep, GLUT3 has been found on the microvillous
junction between the syncytium and trophoblast layer [81]. Interestingly, GLUT3 is only expressed in
one other tissue aside from the placenta, the brain [74,80]. The brain, like the fetus, depends on a constant
supply of glucose in order to sustain energy production. Therefore, expression of GLUT3 in the placenta
may maintain glucose supply to the fetus, even when maternal plasma glucose concentrations are
low [14]. Furthermore, GLUT3 has a higher affinity for glucose than GLUT1 and is therefore more
efficient in transporting glucose at low concentrations [81]. The high affinity of GLUT3 for glucose
means that in conditions where maternal glucose concentrations are lower than normal, GLUT3 may be
the key transporter in tissues where glucose is the primary metabolic substrate [74].
GLUT4 is insulin dependent and its immunostaining was detected in fibroblasts from amnion and
chorion [82]. A strong GLUT4 signal was also observed in intravillous stromal cells, appearing to
co-localize with InsR [83]. GLUT8 was localized to the chorionic epithelial layer and uterine epithelial
cell from mid to late gestation and its expression in placenta increased during late gestation [84,85].
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3.6.2. Placental Amino Acid Transport Systems
The human placenta expresses more than 20 different amino acid transporters [13]. Fetal amino acid
concentrations are generally higher than maternal amino acid concentrations, reflecting an active
transport mechanism across the placenta [13,86]. However, the placenta not only transports amino acids
from mother to fetus but also produces and utilizes amino acids to meet its own metabolic need, and
therefore plays a key role in determining the flux of amino acids into the fetal circulation [9]. Many types
of placental amino acid transporters have been identified and are characterized into distinct
systems [13,86]. There are several major classes of amino acid transporters present in the placenta,
including neutral amino acid transporters, cationic amino acid transporters and anionic amino acid
transporters [87,88].
System A amino acid transporters are an example of neutral amino acid transporters that facilitate the
uptake of small non-essential neutral amino acids such as alanine, glycine and serine. Uptake occurs
against their concentration gradient simultaneously with the transport of extracellular sodium into the
cell. While system A transporters are present on both placental membranes, expression is greater on the
MVM. System A activity contributes to the high intracellular concentration of amino acids such as
glycine, which is exchanged for extracellular essential amino acids by system L transporters [9].
Therefore, system A transporters are important for the placental transport of both non-essential and
essential amino acids [13]. System A consists of three sodium-coupled neutral amino acid transporter
(SNAT) proteins, each encoded by independently regulated genes: SNAT1 (SLC38A1), SNAT2
(SLC38A2) and SNAT4 (SLC38A4) [59,89]. SNAT2 is ubiquitously expressed in mammalian tissues,
while SNAT1 is predominately expressed in the brain, heart and placenta and SNAT4 expressed in the
liver and placenta [89]. Throughout gestation, the activity of system A transporter increases, although
the individual contributions of the three SNATs to total system A activity varies [13]. SNAT1 and 4 are
found on both the MVM and the BM of the placenta [90]. SNAT1 has been shown to play a significant
role in the human term placenta [91]. SNAT4, which has a lower substrate affinity for neutral amino
acids, has a higher contribution in the first trimester placenta than the term placenta [89].
System L transporters are sodium independent exchangers of neutral amino acids. Non-essential
amino acids are exchanged for essential amino acids with aromatic or branched side chains such as
leucine or phenylalanine to allow for transport against their concentration gradient [92]. System L
transporters consist of a heterodimer formed from a light chain protein, large neutral amino acid
transporter (LAT)1 (SLC7A5) or LAT2 (SLC7A8), and a heavy chain transmembrane protein:
4F2hc/CD98 (SLC3A2) [92,93]. 4F2hc and LAT1 expression is higher in term than mid gestation
placentas [93]. Localization of the LAT isoforms are polarized, with LAT1 predominately found on the
MVM and LAT2 on the BM [94], although LAT2 has also been shown to have functional activity in the
MVM [95]. However, localization of LAT2 on the BM allows for the exchange of amino acids between
non-essential amino acids in the fetal circulation and essential amino acids in the syncytiotrophoblast
cytoplasm [96]. Two additional system L light chains, LAT3 and LAT4 have recently been reported in
placental tissues [97,98]. They are localized to the BM and may play an important role in the net efflux
of amino acids to the fetus [99]. While transporting a restricted group of system L substrates (leucine,
isoleucine and phenylalanine), LAT3 and LAT4 also appear to differ from the traditional system L
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transport in that they do not require the co-expression of 4F2hc and function as facilitative diffusion
transporters [99,100].
It is well established that the cationic amino acid transporter (CAT) is the main transporter for cationic
amino acids in MVM [101]. Kamath et al. also found that CAT1 (SLC7A1), CAT2 (SLC7A2), and
CAT4 (SLC7A4) are expressed in cultured trophoblast cells and in BeWo choriocarcinoma cells [102],
supporting the possibility that multiple members of the CAT family are present in BM of the placenta.
CAT is a sodium independent electrogenic transporter, which interacts only weakly with neutral amino
acids and therefore is specific for cationic amino acids.
Anionic or system XAG amino acid transporters are capable of sodium dependent and
D-aspartate-inhibitable glutamate/aspartate transport activity. A family of five anionic amino acid
transporters (excitatory amino acid transporters EAAT1-5) have been cloned and, of these, EAAT1-4
are expressed in the human and rat placenta [103–105]. EAAT1-4 are present in both plasma membranes
of the syncytiotrophoblast and increase over the last trimester [105,106].
3.6.3. Placental Fatty Acid Transporter Systems
Fatty acids are important precursors of bioactive molecules, which are structural components of cells
and provide a major source of energy [13]. Two sources of fatty acids are taken up by the placenta from
the maternal circulation, the esterified fatty acids that are present in triglycerides (TG) and the
nonesterified fatty acids (NEFA) [13]. The primary source of fatty acids taken up by the placenta is
maternal TG because their uptake increases in the last trimester compared with NEFAs [107].
Fatty acid transfer from the mother to the fetus can be accomplished via simple diffusion, as with
NEFAs [107]. However, in late gestation the rate of simple diffusion may not be adequate to supply the
fetus [13,108]. Kazantzis and Stahl stated that the cellular membrane fatty acid transport proteins
(FATPs) are important for the cellular uptake of long chain fatty acids [108]. There are five transport
proteins in humans, including FATP1-4 and FATP6 [109]. FATP1 is present on both the MVM and the
BM, but the exact cellular location of the others remains unknown [110]. Fatty acid translocase (CD36)
is the membrane-associated protein expressed in placenta with the ability to transport fatty acids [110].
Upon entering the syncytiotrophoblast the hydrophobic fatty acids are transported across the cytosol to
the BM or to other sites within the cell where they undergo esterification or beta oxidation. To
accomplish this they bind with fatty acid binding proteins (FABPs) [13]. There are four forms of the
fatty acid binding proteins in the human placenta, including FABP1 and FABP3-5 [111].
We have summarized the major placental changes in morphology and substrate transport capacity
that regulate placental efficiency and fetal growth in normal pregnancies. As we know, placental
insufficiency results in a failure of the placenta to deliver an adequate supply of substrates to the fetus
and IUGR develops. Therefore, several different experimental methods used to produce placental
insufficiency and induce IUGR in animal models and a range of factors that regulate placental growth
and substrate transport capacity have been discussed in human and animal IUGR studies below.
4. The Placenta and Development of Intrauterine Growth Restriction
Intrauterine growth restriction is clinically defined as a birth weight below the tenth centile for
gestational age where the fetus does not meet its growth potential [23,112]. IUGR affects 6% of
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Australian pregnancies [1] and is associated with a high incidence of perinatal morbidity and mortality [7].
IUGR neonates have a greater risk of hypoxic-ischaemic encephalopathy, intraventicular haemorrhage
and necrotizing enterocolitis with longer hospital stays and higher health care costs [23]. Furthermore,
epidemiological, clinical and experimental studies from around the world highlight an association between
a poor intrauterine environment and poor health outcomes in adulthood [7,113–115]. In particular, these
studies have demonstrated a significant relationship between small size at birth and the risk of developing
coronary heart disease, hypertension and type 2 diabetes in adulthood [4–6]. Causes of IUGR can be of
maternal, fetal or placental origin, including maternal smoking, alcohol and drug abuse, genetic defects,
chromosomal abnormalities or placental pathologies [116]. In the developing world, IUGR is likely to
be a consequence of poor maternal nutritional status prior to or during pregnancy whereas, in the
developed world IUGR is commonly a consequence of placental insufficiency [117].
Several different experimental methods have been used to produce placental insufficiency and induce
IUGR in both small and large animal models, and previously discussed in detail [23]. For example,
methodologies include reduction of uterine blood flow by vascular occlusion or ligation in rats, guinea
pigs and sheep, hyperthermia, placental infarction by repetitive embolization in pregnant ewes or uterine
carunclectomy of non-pregnant ewes [23]. As sheep are used in all of these methodologies to induce
IUGR, the sheep models of placental insufficiency are summarized below (Table 2).
Table 2. Summary of experimental models of placental insufficiency and their impact on the
placenta and the fetus.
Experimental Intervention

Impact on the Placenta

Impact on the Fetus

Surgical Umbilical
Artery Ligation
(SUAL)

Isolation and ligation of one
umbilical artery close to
the fetal abdomen

placental infarction causing
↓ umbilical blood flow and
↓ placental substrate
transfer [118,119]

Hypoxemia IUGR

Maternal
Hyperthermia

Exposure of pregnant ewes to
an environment with an
increased ambient temperature

↓ uterine artery flow and
↓ placental weight due to
↑ maternal temperature [2,30]

IUGR

Placental Embolism

Repeated injection of
microspheres (15μm) into the
placenta via the umbilical
artery through a catheter
implanted in the descending
aorta or fetal umbilical vein

block placental capillaries
causing ↓ placental surface
area [120]

Hypoxemia
Hypoglycemia IUGR

Uterine Carunclectomy

Surgical removal of the
majority of the endometrial
caruncles from the uterus of
non-pregnant ewes prior
to conception

↓ placental weight due to
↓ placentomes [116]

Hypoxemia
Hypoglycemia IUGR
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5. Animal Models of Placental Insufficiency
5.1. Single Umbilical Artery Ligation (SUAL)
Single umbilical artery ligation (SUAL) involves the isolation and ligation of one umbilical artery
close to the fetal abdomen [118]. SUAL causes a partial infarction of the placenta, which reduces
umbilical blood flow and causes a reduction in the capacity of the placenta to transfer substrates and
induces IUGR in the sheep fetus [118,119]. Furthermore, SUAL fetuses are significantly smaller than
control fetuses from 117 days gestation and are chronically hypoxaemic (PO2 < 17 mmHg), but not
acidotic in late gestation [121].
5.2. Maternal Hyperthermia
The hyperthermia-induced model of placental insufficiency induces fetal growth restriction by
exposing pregnant ewes to an environment with an increased ambient temperature with a diurnal cycle
of 40 °C for 12 h and 35 °C for 12 h, from ~38 days gestation until ewes are sacrificed at post
mortem [2,122]. Ewes can be exposed to this treatment for ~17 days (early gestation), ~52 days (mid
gestation) or ~96 ± 5 days (late gestation). This hyperthermia treatment results in an increase in maternal
core body temperature from ~39 °C to 40 °C in hyperthermia pregnant ewes [53,123]. It also results in
a redistribution of blood flow toward the peripheral vascular system, leading to a reduction in uterine
and umbilical artery blood flow and a decrease in placental weight and IUGR [2,30].
5.3. Placental Embolism
Placental embolism of the placental vasculature aims to mimic the onset of IUGR in late gestation.
This procedure involves repeated injection of microspheres (15 μm) into the placenta via the umbilical
artery through a catheter implanted in the descending aorta or fetal umbilical vein [124–126]. The
microspheres block the placental capillaries resulting in reduced surface area for the transfer of substrates
from mother to fetus [120]. Placental embolism in late gestation causes acute decreases in placental
substrate supply after each daily injection over a period of 10–20 days, which leads to chronic fetal
hypoxemia, hypoglycemia and IUGR.
5.4. Endometrial Carunclectomy
Uterine carunclectomy limits the number of placentomes after surgical removal of the majority of the
endometrial caruncles from the uterus of nonpregnant ewes prior to conception. This restricts the number
of placentomes that form during pregnancy, consequently limiting placental and fetal growth [116].
Experimental restriction of placental growth results in fetuses that are chronically hypoxaemic and
hypoglycemic [127]. Furthermore, the changes to nutrient supply and fetal blood gases in placentally
restricted (PR) sheep fetuses are similar to those measured in cordocentesis studies of human infants
who are born small for gestational age [116,121]. PR fetuses also have reduced placental and fetal
weights at term [128].
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6. Regulation of Placental Growth and Substrate Transport in IUGR Pregnancy
Fetal growth is dependent on substrate supply, which is dependent on substrate transport and its
regulation. These processes also depend on morphological characteristics of the placenta, such as
placental size, morphology, blood flow and vascularity. Therefore placental nutrient transfer capacity is
specifically regulated by signals of fetal, maternal and placental origin in an effort to control fetal growth.
However, in late gestation, when fetal nutrient demand is at its greatest, the compensatory upregulation
is no longer sufficient to meet fetal demand and thus IUGR develops [129,130]. Here, we focus on the
morphological and functional changes in the regulation of placental growth and substrate transport
capacity in human pregnancy complicated with IUGR and animals models of placental insufficiency.
6.1. Placental Size and Morphology
In human pregnancies, Chen and coworkers have found a significant decrease in villi vascular density
and cell proliferation in both trophoblast and stromal cell compartments within the IUGR placentas
compared with control placentas at 25 to 41 weeks of gestation [131]. Other reports have shown a
decrease in surface area, volume, and number of terminal villi, a reduced number of capillaries as well
as an increased thickness of the exchange barrier in the stroma of IUGR placentas as compared with
placentas from normal pregnancies [132,133]. Undernutrition in guinea pigs during pregnancy increases
barrier thickness and reduces placental weight and placental area involved in nutrient exchange during
late gestation [134]. In contrast, hypoxia during pregnancy cause a reduction in the barrier thickness
between maternal and fetal circulation in the human and guinea pig placenta that has a direct effect on
diffusional exchange [135,136]. In pregnant sheep, the total surface of the cotyledons and surface
occupied by vasculature were greater at high altitude, whereas the number of cotyledons was smaller at
high altitude [137]. These placental morphological changes may improve maternal and fetal exchange
and display an efficient mechanism of adaptation to hypobaric hypoxia.
Experimental restriction of placental size by surgical removal of implantation sites prior to
conception, multiple pregnancy or adverse conditions in early gestation restricts fetal growth, but
increases fetal to placental weight ratio and placental efficiency in late pregnancy [15,53]. Conversely,
an increased fetal to placental weight ratio may suggest fetal adaptations in response to the small
placenta, which maximizes transplacental concentration gradients and/or partitioning of placentally
derived nutrients to support and maintain fetal growth during suboptimal intrauterine conditions [55].
Adverse conditions, such as maternal undernutrition and hypoxemia resulted in increased eversion of
placentomes and an increased proportion of type C and D placentomes in late gestation sheep
fetuses [138,139]. In contrast, adverse intrauterine conditions induced by umbilical cord compression is
associated with an increased proportion of type A and B, and fewer type C- and D placentomes during
late gestation in sheep [140]. Therefore, adverse conditions in the intrauterine environment determine
placental morphology during late gestation depending on the type and duration of the insult.
6.2. Oxygen Supply/Uptake, Blood Flow and Vascularity
In situations of placental insufficiency and IUGR, there appears to be an underdevelopment of the
placental epithelial sites, with low hindrance to transplacental O2 diffusion reducing the surface area of
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exchange between the uterine and umbilical circulations, and resulting in decreased fetal umbilical
oxygen supply [30,132]. Under hypoxic conditions, hypoxia inducible factor (HIF)-1, which consists of
two subunits HIF-1α and HIF-1β, acts on the cell nucleus and regulates the expression of genes with
hypoxia response element (HRE). HIFs recruit mechanisms to increase oxygen supply (erythropoiesis,
angiogenesis, and vasodilation), decrease oxygen demand (increased glycolysis coupled with decreased
oxidative metabolism), and regulate the cell cycle, apoptosis, and autophagy [141]. In vitro studies have
demonstrated that hypoxia can affect the proliferation, differentiation, and invasion of cytotrophoblast
cells [142]. Following a three day exposure to low oxygen, there was decreased HIF-1α and unchanged
HIF-2α mRNA expression in cultured murine ectoplacental cones [143]. Hypoxia resulted in an increase
in the transcription and translation of VEGF in cultured placental fibroblasts [144]. Low oxygen levels
also resulted in a shift of the angiopoietin-1: angiopoietin-2 ratio in favor of angiopoietin-2, leading to
vessel instability, angiogenesis and vessel remodeling [145].
Morphological studies show that physiological remodelling of the maternal uterine vasculature into
spiral arteries is deficient in IUGR pregnancies due to inadequate trophoblast invasion [146,147]. This
results in maternal blood entering the placenta at an abnormally high rate, which causes damage to the
placental villi and may harm endocrine and transport functions of the placenta. The intensity of VEGF-A
immunostaining in syncytiotrophoblast was significantly reduced in placental villous tissue from
pregnancies complicated by IUGR and preeclampsia compared with the control group [148]. However,
it has been shown that the expression of VEGF-A and bFGF was significantly higher in cytotrophoblasts,
syncytiotrophoblasts, extravillous trophoblasts, vascular smooth muscle cells, chorionic villous stromal
cells and villous vascular endothelial cells of the IUGR placenta when compared with those collected
from normal-term pregnancies using semi-quantitative immunohistochemistry [149]. This suggests that
these factors play a role in promoting increased endothelial cell proliferation, migration and pathological
angiogenesis. Similarly in sheep, hyperthermia-induced placental restriction resulted in increased uterine
blood flow and increased VEGF, angiopoietin-1, angiopoietin-2 and TIE-2 expression in the fetal portion
(cotyledon) of the placentome in early gestation as well as reduced expression in FLT-1 and FLK-1 in
the cotyledonary tissue in mid gestation, suggesting a disorganized fetal capillarisation and angiogenesis
as well as compensatory transport capacity for the fetal circulation to uptake nutrients from the maternal
circulation, which fails to maintain placental and fetal growth [53,54,123]. These alterations in
angiogenic growth factors could impair normal placental vascular development and may contribute to
the development of placental insufficiency, and ultimately intrauterine growth restriction.
6.3. IGFs
In knockout mice with a deletion of the placental-specific transcript (P0) of the Igf2 gene, placental
surface area is reduced and placental thickness increased, leading to reduced placental growth and fetal
growth restriction [60,61]. Placental IGF-I mRNA expression was lower in the growth-restricted groups
compared with normal pregnancies [150]. Similarly, the mRNA expression of IGF1, IGFBP1 and human
placental growth hormone was significantly lower in placentas from human IUGR pregnancies
compared with that in placentas of fetuses with normal growth [151]. However in sheep, caruncle IGF1
mRNA expression was increased at 90 days gestation in the placentas of hyperthermia-induced IUGR
compared with the control group [152]. Cotyledon IGF2 and caruncle IGFBP4 mRNA expression were
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also elevated at 55 days gestation in these placentas [152]. In contrast, maternal hypoxia in mice
from mid to late gestation resulted in a decrease in placental mRNA expression of IGF2, IGF1R and
IGF2R [153].
6.4. Apoptosis, Autophagy and Glucocorticoid Action
Placentas from women with IUGR pregnancies show enhanced apoptosis when compared with those
from normal pregnancy [154,155]. Cultured trophoblasts exposed to hypoxia alone show an upregulation
of p53 activity and BCL-2-like protein 4 (BAX) expression and decreased expression of the anti-apoptotic
BCL-2, all of which promote apoptosis [156]. Hypoxia/re-oxygenation results in even more marked
apoptosis regulated by increased expression of the pro-apoptotic BAX and BCL-2 homologous
antagonist (BAK) mRNA and protein and reduced expression of BCL-2 mRNA in human placental
villous tissues [157]. Expression of p53 and the active form of caspase-3 is upregulated in villi from
IUGR compared to control pregnancies, and the increase is predominantly in the villous trophoblast in
humans [158,159]. The association between altered trophoblast cell turnover in IUGR and increased p53
expression was also shown to be reminiscent of that following exposure to hypoxia [160].
Compared with normal pregnant women, women with IUGR had increased placental levels of
autophagy-related proteins including LC3B-II, beclin-1, DRAM, and p53 [161]. Furthermore, hypoxia
induces apoptotic and autophagic changes in primary human cytotrophoblasts [162].
Placental 11βHSD2 activity was significantly reduced in deliveries complicated by IUGR compared
with the term deliveries and with appropriately grown preterm deliveries, suggesting that glucocorticoids
may, in part, contribute to impaired fetal growth closely controlled through placental 11βHSD2
expression [71]. There is evidence that exposure of the pregnant sheep to maternal undernutrition for a
period extending beyond the preimplantation period, from 60 days before and the first 30 days after
conception or from early to mid gestation (between 28 and 78 days gestation), results in a decrease in
placental 11βHSD2 expression or activity [72,163]. In mice, maternal hypoxia during mid to late
gestation resulted in a decrease in placental glucocorticoid receptor (GR) mRNA expression as well as
placental 11βHSD2 mRNA and protein expression [153]. A previous study by Mericq et al found a
lower expression and activity of 11βHSD1 in both chorionic and basal plates of the placentas from full
term small for gestation age newborns compared with those in the placentas from appropriate for
gestational age newborns, suggesting a possible compensatory mechanism to diminish the higher cortisol
concentrations in fetuses with IUGR [164].
6.5. Glucose Transport Systems
Alterations in placental glucose transport have been implicated in adverse perinatal conditions such
as IUGR and fetal hypoxia [165]. As glucose transport is dependent on the glucose concentration
gradient from mother to fetus, the IUGR pregnancy has increased the transplacental glucose gradient
and glucose uptake across the placenta [10] and this represents an example of how the IUGR fetus adapts
to restricted placental size. In carunclectomized ewes with smaller placentas and a larger proportions of
type D placentomes, the rate of glucose transfer to the fetus per gram of placenta is greater than that in
controls [166,167]. Exposure to hypoxic conditions resulted in an upregulation in GLUT1 protein
abundance and trans-epithelial glucose transport in BeWo choriocarcinoma cells [168]. GLUT3 mRNA
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expression and protein abundance in the trophoblast on the maternal aspect of the placenta was increased
in the full-term IUGR placenta compared with normal placenta [169]. Increased placental GLUT3
expression was associated with increased activation of placental HIF-1α, suggesting that hypoxia may
play a role in the upregulation of GLUT3. However, placental GLUT1 mRNA expression was decreased
in the maternal aspect of the IUGR placenta and GLUT4 mRNA expression was increased in the fetal
aspect of the IUGR placenta when compared with the control pregnancies, although there was no
difference in placental GLUT1 or GLUT4 protein abundance between the treatment groups [169]
(Table 3). Similarly, placental GLUT1, but not GLUT3 immunostaining in the terminal villi of severe
preeclampsia cases (both with and without IUGR) was significantly lower compared with the control
group [170]. Chronic hypoxia in vivo with high altitude pregnancies also resulted in a decrease in GLUT1
expression in the BM but not MVM of the placenta, leading to reduced nutrient supply and fetal
growth [171]. In mice, maternal hypoxia during mid to late gestation resulted in a decrease in placental
GLUT1 mRNA and protein expression in female fetuses, but no change in placental GLUT3 mRNA
expression in both female and male fetuses [153]. Another study demonstrated that GLUT1 protein
abundance is not altered in IUGR babies when compared to those that are appropriate for gestational age
(AGA) [172]. Placental GLUT8 mRNA expression and protein abundance was decreased in late
gestation in a sheep model of IUGR caused by placental insufficiency, which may contribute in part to
the placental glucose transport deficit that occurs in this model [84]. Taken together, these data along
with amino acid and fatty acid transport systems mentioned below suggest that the regulation of nutrient
transport in the IUGR pregnancies may depend on the timing and type of the insult, and be species-specific
and different from in vivo and in vitro studies.
Table 3. Summary of human and sheep models of IUGR and their impact on oxygen transfer,
placental glucose, amino acid and fatty acid transporters.
Models of IUGR

Impact on Glucose Transporters

Impact on Amino
Acid Transporters

Impact on Fatty
Acid Transporters

Human IUGR

↓ GLUT1 mRNA, ↔ GLUT1 protein [169]
↑ GLUT4 mRNA, ↔ GLUT1 protein [169]
↑ GLUT3 mRNA & protein [169]
↓ GLUT1 protein [171]
↓ GLUT1 protein
↔ GLUT3 protein [170]
↔ GLUT1 protein [172]

↓ System A
transporter activity
[173,174]
↓ SNAT2 mRNA &
protein [175]

NS

Surgical Umbilical Artery
Ligation (SUAL)

NS

NS

NS

Maternal Hyperthermia

↓ GLUT8 mRNA & protein

↑ LAT-1 & LAT-2
mRNA [19]

NS

Placental Embolism

NS

NS

NS

Uterine Carunclectomy

NS

NS

NS

Sheep

NS, not studied.
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6.6. Amino Acid Transport Systems
In the IUGR placenta the different amino acid transport systems are affected. Tracer studies of
placental amino acid transport have demonstrated that there is a significant reduction in the
transplacental flux/fetal turnover ratios of essential amino acids [176–178]. For example, reduced uptake
of leucine and lysine was found in vesicles from human IUGR placenta compared with the controls,
suggesting decreased activity of placental transporters for cationic and neutral amino acids [176].
Similarly, there was a reduction of maternal leucine flux into the placenta and fetus in the hyperthermia
sheep model of IUGR [178]. However, studies of fetal plasma amino acid concentrations have
produced inconclusive results. Although earlier reports showed decreased fetal plasma amino acid
concentrations [178], subsequent human and animal studies showed maintained or increased amino acid
concentrations [22,177,179]. In severely growth restricted sheep fetuses, where placental and fetal
weights are reduced by 40%–60%, umbilical uptake of oxygen, glucose and essential amino acids is
significantly reduced, whereas the fetal/maternal ratio of the amino acids that are transported from the
placenta to fetus showed normal or elevated fetal concentrations compared to control fetuses [22,30]. A
previous study has shown that transplacental and total placental clearance of a branched-chain amino
acid analogue, the non-metabolisable neutral amino acid aminocyclopentane-l-carboxylic acid per 100 g
placenta, were significantly reduced in a sheep model of hyperthermia-induced IUGR, suggesting
impaired placental non-essential amino acid transport in the IUGR placenta [180].
In normal pregnancy, system A transporter activity was shown to be the highest in the smallest babies
per milligram of microvillous protein [181]. In contrast, placental system A transporter activity
was not only reduced in IUGR compared with normal pregnancies but also related to the severity of
IUGR [173,174]. Placental SNAT2 mRNA expression and syncytiotrophoblast immunostaining were
significantly decreased in IUGR placentas with reduced umbilical blood flows compared with those in
control placentas [175]. Hypoxia also decreases placental system A transport and activity in full-term
human trophoblasts [182]. In mice, maternal hypoxia during mid to late gestation resulted in an increase
in placental GLUT1 mRNA expression in female fetuses, but no change in placental SNAT4 mRNA
expression. There was also a decrease in placental SNAT2 mRNA expression in both female and male
fetuses [153]. Interestingly, placental LAT-1 and LAT-2 mRNA expression was elevated in the
moderately growth restricted sheep fetuses where placental and fetal weight was reduced by 25%
compared with the control placenta [19].
6.7. Fatty Acid Transport Systems
Hypoxia enhances the expression of FABP1, -3, and -4 in term human trophoblasts, suggesting that
FABPs play a role in fat accumulation in the hypoxic placenta [111]. Similarly, hypoxia also resulted in
increased FATP2 expression and reduced FATP4 expression in cultured primary term human
trophoblasts [183]. However, placental CD36 mRNA expression was unaltered in human pregnancy
complicated with IUGR [184].
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7. Conclusions
The placenta is the main interface between the fetus and mother. Placental insufficiency results in a
failure of the placenta to deliver an adequate supply of substrates to the fetus and IUGR develops. A
range of human and animal studies in IUGR pregnancies have suggested that placental restriction and
insufficiency may result in a series of placental changes such as altered placental growth and placental
substrate transport capacity, increased apoptosis and autophagy and increased glucocorticoid action
(Figure 1). Such placental morphological and functional changes may consequently lead to decreased
fetal growth and IUGR, which is modified by compensatory changes in placental efficiency. We have
also noted that there are different patterns of placental changes associated with the human IUGR
pregnancy and animal models of placental insufficiency induced IUGR. These differences may be
dependent on the nature of the causes of IUGR, the time, duration and severity of insult exposure, species
and in vivo or in vitro studies. While no model system completely encapsulates complete human IUGR,
these model systems do allow us to carefully dissect aspects of the issue so as to further expand our
understanding of the cellular and molecular mechanisms involved, and promote the development of
therapeutic interventions.

Figure 1. Summary of the placental adaptations that occur in the placental
insufficiency-induced IUGR fetus and contribute to decreased fetal growth.
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